St. Jude Medical Says FDA Approves BurstDR Stimulation - Quick Facts

(RTTNews) - St. Jude Medical, Inc. (STJ), announced the U.S. approval of BurstDR stimulation, a physician-designed form of spinal cord stimulation or SCS clinically proven to provide superior outcomes for patients with chronic pain over traditional SCS therapy.

With the FDA approval of BurstDR stimulation, which is exclusive to St. Jude Medical, the company aims to help patients find relief from their pain and suffering while also providing patients a better experience with their chronic pain therapy.

Chronic pain, which affects about 1.5 billion people worldwide, is a complex and challenging condition for physicians to manage and a heavy burden for patients who find their lives profoundly limited by their pain. Many patients often move from treatment option to treatment option seeking pain relief, only to find a partial or incomplete response to therapy.

According to St. Jude Medical, its proprietary BurstDR stimulation works differently from other stimulation designs by utilizing intermittent "burst" pulses designed to mimic the body's natural nerve impulse patterns.

The stimulation was introduced after nearly a decade of research and study in collaboration with Prof. Dirk De Ridder, who filed the therapy's initial patents in 2004.

St. Jude noted that with FDA approval of BurstDR stimulation, patients who receive new implants of the St. Jude Medical Proclaim Elite and Prodigy MRI spinal cord stimulation systems will have immediate access to the new therapy.

Combined, the Proclaim Elite SCS System and BurstDR stimulation offers patients the advantages of the St. Jude Medical Invisible Therapy portfolio and an entirely recharge free option, allowing patients to focus on their lives instead of their pain.